ENTA
Enanta Pharmaceuticals, Inc.·Healthcare
14.11
1.147%(+0.16)
Market ClosedLast Updated: — ET
52W L: $4.5552W H: $17.15
ENTA NEWS
businesswire.com
4d ago
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data on zelicapavir, an oral, once-daily, N-protein inhibitor, in development for the treatment of (RSV) have been accepted for two oral presentations at the European Society of Clinical Microbiology & Infectious Diseases Global 2026 (ESCMID) being held April 17-21.
defenseworld.net
Apr 3
Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below 200 Day Moving Average – Should You Sell?
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA - Get Free Report) passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $12.73 and traded as low as $12.61. Enanta Pharmaceuticals shares last traded at $13.14, with a volume of 112,824 shares. Analysts Set New Price Targets Several equities analysts
businesswire.com
Mar 30
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data from the Company's STAT6 inhibitor program will be presented in four posters at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists (AAI), being held April 15-19, 2026 in Boston, MA. Details of the presentations are as foll.
businesswire.com
Mar 3
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that members of management will participate in a fireside chat at The Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 10:45 a.m. ET in Miami Beach, FL. A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “.
zacks.com
Feb 12
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
businesswire.com
Feb 10
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company's KIT inhibitor in development for the treatment of mast cell-mediated, Type 2 immune diseases, will be presented in two poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeti.
